AwardedGermanyGoodsFramework agreement
Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V zu der Wirkstofffixkombination Sofosbuvir/Velpatasvir
- Published
- Published 15 July 2026
Overview
AOK Baden-Württemberg has awarded a pharmaceutical rebate agreement under § 130c SGB V for the fixed-dose combination Sofosbuvir/Velpatasvir (Epclusa®) to Gilead Sciences GmbH as of 7 July 2026. The agreement governs rebates for this patent-protected medication; the exact contract value cannot be determined due to unknown factors and is therefore stated as a notional value based on current threshold amounts.
Key details
- Country
- Germany
- Status
- Awarded
- Category
- Goods
- Procedure
- Direct
- Contract type
- Framework agreement
- Published
- 15 July 2026
Pharmaceutical products
Award outcome
- Award date
- 7 July 2026
- Contract period
- 1 July 2026 → 30 June 2028
- Gilead Sciences GmbH
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
15 July 2026
Contracting authority
AOK Baden-Württemberg
Procuring entityStuttgart, Germany
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.